Sugi Predict

Sugi Predict / Compounds / SCHEMBL18727768

SCHEMBL18727768

SCHEMBL18727768

OCc1ccc2nc(Br)cn2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP3K5 Q99683 2/20 0.44
▸ METTL3 Q86U44 5/20 0.38
▸ PIK3CG P48736 1/20 0.38
▸ CYP2C9 P11712 1/20 0.37
▸ NR4A2 P43354 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ TYR P14679 1/20 0.36
▸ APP P05067 5/20 0.35
▸ FYN P06241 1/20 0.34
▸ RAB9A P51151 3/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ PAX8 Q06710 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ POLB P06746 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ PDCD1 Q15116 1/20 0.33
▸ CD274 Q9NZQ7 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ KEAP1 Q14145 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18727784 0.79 PDCD1 (0.54) METTL3SMN1; SMN2PDCD1CD274
SCHEMBL8829997 0.78 MAP3K5 (0.47) MAP3K5METTL3CYP2C9NR4A2KCNH2
SCHEMBL22528949 0.75 METTL3 (0.44) MAP3K5METTL3CYP2C9NR4A2KCNH2
SCHEMBL2249756 0.75 METTL3 (0.44) MAP3K5METTL3CYP2C9NR4A2KCNH2
SCHEMBL29543551 0.75 METTL3 (0.42) MAP3K5METTL3RAB9ANPC1KDM4E
SCHEMBL24818616 0.74 MAP3K5 (0.44) MAP3K5METTL3CYP2C9NR4A2KCNH2
SCHEMBL22499188 0.73 METTL3 (0.42) MAP3K5METTL3CYP2C9NR4A2KCNH2
SCHEMBL16867101 0.72 NPC1 (0.58) MAP3K5PIK3CGAPPRAB9ANPC1
SCHEMBL13359717 0.71 NPC1 (0.68) CYP2C9NR4A2KCNH2APPRAB9A
SCHEMBL31732651 0.71 APP (0.50) MAP3K5PIK3CGAPPRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590062-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2026-03-31 — — US disclosed
EP-3365340-B1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORP (US) 2022-08-10 — — EP disclosed
US-11407749-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2022-08-09 — — US disclosed
EP-4026835-A2 PD-1/PD-L1 INHIBITORS Gilead Sciences, Inc. (US) 2022-07-13 — — EP disclosed
US-20210347771-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2021-11-11 — — US disclosed
US-20210323922-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2021-10-21 — — US disclosed
EP-3612525-A1 PD-1/PD-L1 INHIBITORS Gilead Sciences, Inc. (US) 2020-02-26 — — EP disclosed
CN-110799509-A PD-1/PD-L1 inhibitors 吉利德科学公司 2020-02-14 — — CN disclosed
US-20190144439-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2019-05-16 — — US disclosed
US-20190144439-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2019-05-16 — — US disclosed
WO-2018195321-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2018-10-25 — — WO disclosed
US-20180305315-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. 2018-10-25 — — US disclosed
EP-3365340-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS Incyte Corporation (US) 2018-08-29 — — EP disclosed
WO-2017070089-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2017-04-27 — — WO disclosed
WO-2017070089-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2017-04-27 — — WO disclosed
US-20170107216-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-04-20 — — US disclosed
US-20170107216-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-04-20 — — US disclosed
US-20170107216-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323922-A1 PD-1/PD-L1 INHIBITORS CD274, PDCD1, PDCD1LG2 MAP3K5 1301/4885METTL3 4640/4885PIK3CG 2589/4885
US-20190144439-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS MAP3K5 3853/4885METTL3 4366/4885PIK3CG 2304/4885
US-11407749-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS MAP3K5 3853/4885METTL3 4366/4885PIK3CG 2304/4885
US-12590062-B2 PD-1/PD-L1 inhibitors CD274, PDCD1LG2, PDCD1 MAP3K5 3992/4885METTL3 2477/4885PIK3CG 4240/4885
US-20170107216-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS MAP3K5 3853/4885METTL3 4366/4885PIK3CG 2304/4885
US-20210347771-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS MAP3K5 3853/4885METTL3 4366/4885PIK3CG 2304/4885
US-20180305315-A1 PD-1/PD-L1 INHIBITORS CD274, PDCD1, PDCD1LG2 MAP3K5 1301/4885METTL3 4640/4885PIK3CG 2589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.